logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Searching for a New Promising Development-Stage Biotech Firm We Found and Picked This One

Krystal Biotech Krystal Biotech ( KRYS ) is  a gene therapy firm focused on developing topical intradermal therapeutics for rare dermatological diseases. It developed its a gene therapy product KB103 for the treatment of the broad Dystrophic epidermolysis bullosa ( DEB)...

Read More

June 25, 2019

0

Has the Time Come for Curis Inc to Flex Its Muscles?

Curis Inc IND Application Cleared by the US FDA Curis Inc ( CRIS ) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CI-8993, the first-in-class monoclonal anti-VISTA antibody. Continue reading...

Read More

June 10, 2020

0

Atossa Genetics Has Promising News

Atossa Genetics Promising News for Endoxifen Atossa Genetics ( ATOS )   has promising news from a Phase 2 trial of its topical Endoxifen for mammographic breast density ( MBD ) reduction.     Preliminary analysis from a recently completed Phase...

Read More

June 27, 2019

0

Small Biotech Firms That Can Become Top-Tier Giants

Small Biotech Firms That Can Become Top-Tier Biotech Giants We Start With... Abeona Therapeutics Abeona Therapeutics ( ABEO )   is a clinical-stage biopharmaceutical gene and cell therapy company. In September 2016 Abeona acquired an exclusive  worldwide license of a...

Read More

July 2, 2019

0

Celldex Therapeutics Doses the First Patient with its CDX-0159 Product for Chronic Spontaneous Urticaria

Celldex Therapeutics After an expected resurrection, Celldex Therapeutics ( CLDX ) stock recovered and went as high as over $19 from less than $2 after an exaggerated selloff caused by  investors following the failure to treat the still untreatable glioblastoma...

Read More

October 13, 2020

0

Reata Pharmaceuticals Stock Soared

Reata Pharmaceuticals Stock is Flying High Here is another example of why analysts can no longer use the same old measures to evaluate the biotechnology firms. They cannot continue to ignore the values of the firms’ technologies and very promising...

Read More

June 11, 2020

0

Sangamo and Pfizer Announce Gene Therapy SB-525 Results in Hemophilia Patients and More

Sangamo and Pfizer Gene Therapy SB-525 Resulted in a Sustained Increase in Factor VIII Levels in Hemophilia Patients Sangamo Therapeutics ( SGMO ) and Pfizer ( PFE ) updated results from the Phase 1/2 Alta study, evaluating investigational SB-525 gene...

Read More

July 8, 2019

0

Are Illumina's 2019 Challenges Transitory?

Illumina Stock Dropped Following Their Preliminary Revenue Announcement Illumina ( ILMN )  stock dropped 16% following the firm's announcement of preliminary revenue for the second quarter of the fiscal year 2019 and updated its 2019 revenue guidance. According to the...

Read More

July 12, 2019

0

Exelixis Has Good News Today and More is Expected

Exelixis and Bristol-Myers Squibb sNDA and sBLA Accepted by the FDA Exelixis ( EXEL ) and Bristol-Myers Squibb ( BMY ) announced that the United States FDA has accepted the supplemental Biologics License Application ( sBLA ) and supplemental New...

Read More

October 19, 2020

0

Exelixis: Encouraging Results from Cabozantinib Trial and a Good Decision by the Firm

Exelixis is Expanding Cohorts for COSMIC-021, the Phase 1b Trial for Cabozantinib  From Exelixis ( EXEL ) we learned about its decision to expand the two original cohorts, and the addition of four new cohorts, to the protocol for COSMIC-021;...

Read More

July 15, 2019

0

  • Previous
  • 1
  • 2
  • ...
  • 98
  • 99
  • 100
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy